Repare Therapeutics to Participate at the 19th Annual Morgan Stanley Virtual Global Healthcare Conference

Rhea-AI Summary

Repare Therapeutics Inc. (NASDAQ: RPTX), a clinical-stage precision oncology company, will participate in a fireside chat at the 19th Annual Morgan Stanley Virtual Global Healthcare Conference on September 9 at 2:45 p.m. ET. The event will highlight the company's proprietary synthetic lethality approach in cancer therapy development, particularly through its SNIPRx® platform. Repare's pipeline includes key products such as RP-3500, an ATR inhibitor in Phase 1/2 trials, and RP-6306, a PKMYT1 inhibitor in Phase 1 trials. A live webcast of the chat will be available on the company's website.

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)-- Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced that members of its senior management team will participate in a fireside chat at the 19^th Annual Morgan Stanley Virtual Global Healthcare Conference on Thursday, September 9 at 2:45 p.m. Eastern Time.

A live webcast of the fireside chat can be accessed in the Investor section of the Company’s website at https://ir.reparerx.com/news-and-events/events. A replay of the webcast will be archived on the Company’s website for 30 days.

About Repare Therapeutics, Inc.

Repare Therapeutics is a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx^® platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. The Company’s pipeline includes its lead product candidate RP-3500, a potential leading ATR inhibitor currently in Phase 1/2 clinical development, its second clinical candidate, RP-6306, a PKMYT1 inhibitor currently in Phase 1 clinical development, a Polθ inhibitor program, as well as eight other early-stage, pre-clinical programs. For more information, please visit reparerx.com.

SNIPRx^® is a registered trademark of Repare Therapeutics Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210902005249/en/

Repare Contact:



Steve Forte

Chief Financial Officer

Repare Therapeutics Inc.

info@reparerx.com



Investors:



Kimberly Minarovich

Argot Partners

repare@argotpartners.com



Media:

David Rosen

Argot Partners

david.rosen@argotpartners.com

212-600-1902

Source: Repare Therapeutics Inc.

FAQ

When is Repare Therapeutics participating in the Morgan Stanley Conference?

Repare Therapeutics will participate in the Morgan Stanley Virtual Global Healthcare Conference on September 9 at 2:45 p.m. ET.

What is the significance of Repare Therapeutics' SNIPRx platform?

Repare Therapeutics' SNIPRx platform enables the discovery and development of targeted cancer therapies, focusing on genomic instability.

What clinical stages are RP-3500 and RP-6306 in?

RP-3500 is currently in Phase 1/2 clinical development, while RP-6306 is in Phase 1 clinical development.

How can I watch the Repare Therapeutics fireside chat?

The fireside chat can be accessed live through the Investor section of Repare Therapeutics' website.

What are the key products in Repare Therapeutics' pipeline?

Repare's pipeline includes RP-3500 (ATR inhibitor), RP-6306 (PKMYT1 inhibitor), and various early-stage pre-clinical programs.